Baird Financial Group
EBS icon

Baird Financial Group’s Emergent Biosolutions EBS Stock Holding History

Baird Financial Group’s Portfolio EBS Stock Details EBS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q3 		– Sell
-12,357
Closed -$90.8K – 1723
2023
Q2 		$90.8K Buy
+12,357
New +$115K ﹤0.01% 1657
2022
Q3 		– Sell
-8,192
Closed -$254K – 1735
2022
Q2 		$254K Buy
8,192
+879
+12% +$30K ﹤0.01% 1612
2022
Q1 		$300K Buy
7,313
+607
+9% +$26.8K ﹤0.01% 1614
2021
Q4 		$292K Buy
6,706
+3
+0% +$136 ﹤0.01% 1688
2021
Q3 		$336K Buy
+6,703
New +$406K ﹤0.01% 1625

Other funds holding EBS

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Hotchkis & Wiley Capital Management
Hotchkis & Wiley Capital Management Los Angeles, California $32.4B AUM 17.21% 1-Year Est. Return
Charles Schwab
Charles Schwab San Francisco, California $654B AUM 26.35% 1-Year Est. Return
Jacobs Levy Equity Management
Jacobs Levy Equity Management Florham Park, New Jersey $23.8B AUM 25.4% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Two Sigma Advisers
Two Sigma Advisers New York $51.4B AUM 31.07% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return

Baird Financial Group's EBS Position: Q3 2023 in Review

Baird Financial Group sold out of Emergent Biosolutions (EBS) in Q3 2023, closing a stake of 12,357 shares — an estimated $90.8K sold.

Baird Financial Group first reported a position in EBS in Q3 2021 and held it in 5 quarters. The position peaked at $336K in Q3 2021. 162 funds tracked by Wall St. Rank hold EBS as of Q3 2023.

  • Baird Financial Group reported no remaining Emergent Biosolutions position as of Q3 2023 after selling out during the quarter.
  • Baird Financial Group sold 12,357 Emergent Biosolutions shares in Q3 2023, an estimated $90.8K.
  • Baird Financial Group first reported a position in Emergent Biosolutions in Q3 2021 and held it in 5 quarters.
  • Baird Financial Group's Emergent Biosolutions position peaked at $336K in Q3 2021.
  • 162 funds tracked by Wall St. Rank held Emergent Biosolutions as of Q3 2023.

Based on Baird Financial Group's 13F filing for Q3 2023, filed 13 Nov 2023.